Bionano Genomics EBITDA TCAC 3A

Que fait Bionano Genomics ? Bionano Genomics, Inc. generates revenue through the development and marketing of the Saphyr system, a platform for structural variation detection in genome analysis. The company sells Sequencing for Discovery Research, targeting researchers seeking single nucleotide variations linked to disease or therapy, and Cytogenetics, which provides clinical diagnostics for known disease-associated variations. Lineagen, Inc., the subsidiary, offers molecular diagnostics services for individuals, contributing to the company's revenue streams. The primary buyers are research institutions and clinical laboratories focused on genetic diagnostics and therapeutic development. The Saphyr system enables ultra-sensitive detection of structural variations, accelerating research into new diagnostics and therapeutic targets. Cytogenetics services are utilized by clinical labs for diagnosing conditions tied to chromosomal changes, while Sequencing for Discovery Research supports academic and pharmaceutical research on disease mechanisms. Lineagen’s molecular diagnostics cater to individual patients requiring genetic testing for personalized healthcare solutions. Bionano’s products serve segments including life sciences research, clinical diagnostics, and personalized medicine. The Saphyr system is central to both research and clinical applications, bridging genomic analysis with practical diagnostic tools. Lineagen’s services directly support patient care through molecular diagnostics, expanding the company’s reach into healthcare delivery. Bionano Genomics est l'une des entreprises les plus populaires sur Eulerpool.